UPZENXIA
Live / Allowed — Published for opposition (as of 17 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 26 Sept 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99414734
- Mark type
- Stylized text
- Filed
- 26 Sept 2025
- Published for opposition
- 17 Mar 2026
- Attorney of record
- Marilyn F. Kelly
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; Antivirals; Antibodies for medical purposes; Biological preparations for the treatment of cancer; Anticoagulants; Stem cells for medical purposes; Radiopharmaceutical preparations for the treatment of cancer and solid tumors; Diagnostic radiopharmaceutical preparations; Diagnostic preparations for medical purposes
Owner
- Bristol-Myers Squibb Company, Princeton, NJ, US
- Bristol-Myers Squibb Company, Princeton, NJ, US
Prosecution history
- 17 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Mar 2026 — PUBLISHED FOR OPPOSITION
- 11 Mar 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 Feb 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 18 Feb 2026 — ASSIGNED TO EXAMINER
- 16 Feb 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 26 Sept 2025 — APPLICATION FILING RECEIPT MAILED
- 26 Sept 2025 — NEW APPLICATION ENTERED